Figure 1 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors

Christopher H. Lieu; Heinz–Josef Lenz; Al B. Benson; Xue Meng; Uk-Il Kim; Song Hyun Kim; Kyungjin Kim; Moo Je Sung

doi:10.1158/2767-9764.30285019

October 6, 2025

Figure 1 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors

View at Publisher

Ask AI

Bookmark

Share

Key Points

Best change in target lesions from baseline indicates treatment impact on tumor size.
Patients with RCC showed marked responses, with some achieving stable disease.
The evaluation followed the Response Evaluation Criteria in Solid Tumours 1.1 framework.
The findings support further exploration of basroparib's role in treating advanced solid tumors.

Implication

Phase I study evaluates the safety and efficacy of basroparib in advanced-stage tumors, indicating potential benefits for patients with RCC.

Abstract

Best change (%) in target lesion from baseline. Note: “▲” marks patients with RCC; SD, stable disease in overall evaluation following Response Evaluation Criteria in Solid Tumours 1.1.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lieu et al. (2025) studied this question.

synapsesocial.com/papers/68e5c1ba6950a706b22b537c https://doi.org/10.1158/2767-9764.30285019

View at Publisher

Ask AI

Bookmark

Share

Figure 1 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure 1 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers